Marksans Pharma Ltd
NSE: MARKSANS BSE: 524404
₹216.17
(0.57%)
Sat, 30 May 2026, 01:44 pm
Market Cap98.4B
PE Ratio27.19
Dividend0.37
Health Technology
Pharmaceuticals: Major
24.5KMarksans Pharma Analysis
dividend
- Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Marksans Pharma's dividends as it is not paying a notable one for India.
- Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Marksans Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Marksans Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Marksans Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Marksans Pharma is profitable, therefore cash runway is not a concern.
- Marksans Pharma is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (880.5%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 24.8x debt.
- Marksans Pharma's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (31.5% vs 3.7% today).
- Interest payments on debt are well covered by earnings (EBIT is 18.9x coverage).
- Marksans Pharma's level of debt (3.7%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- Mark's remuneration is lower than average for companies of similar size in India.
- Mark's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Marksans Pharma board of directors is less than 3 years, this suggests a new board.
misc
- Marksans Pharma is not covered by any analysts.
- Marksans Pharma has significant price volatility in the past 3 months.
past
- Marksans Pharma's 1-year earnings growth exceeds its 5-year average (50.2% vs -1.4%)
- Marksans Pharma used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Marksans Pharma has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Marksans Pharma's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (50.2% vs 22.7%).
- Marksans Pharma's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Marksans Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Marksans Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Marksans Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Marksans Pharma is good value based on earnings compared to the IN Pharmaceuticals industry average.
- 524404 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524404 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524404 is up 65.7% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524404 is up 65.7% outperforming the market in India which returned 8% over the past month.
- Marksans Pharma is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Marksans Pharma is overvalued based on earnings compared to the India market.